
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>0. ACG Clinical Guideline: Diagnosis & Management of **Eosinophilic Esophagitis**  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>0. ACG Clinical Guideline: Diagnosis &amp; Management of <strong>Eosinophilic Esophagitis</strong>  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>1. Study Design &amp; Methodology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">GRADE methodology applied throughout  </li>
<li style="margin-left: 0px;">Systematic literature search (PubMed)  </li>
<li style="margin-left: 0px;">PICO framework for all questions  </li>
<li style="margin-left: 0px;">Evidence graded: high → very low  </li>
</ul>
<details><summary><strong>1.1 Guideline Development  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Multidisciplinary panel (adult &amp; pediatric GI, allergist)  </li>
<li style="margin-left: 0px;">Regular meetings; consensus voting  </li>
</ul>
</div></details>
<details><summary><strong>1.2 Evidence Review Process  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Librarian performed exhaustive PubMed searches  </li>
<li style="margin-left: 0px;">Cross‑checked with known RCT registries  </li>
<li style="margin-left: 0px;">Selected highest‑quality studies per PICO  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. Population Characteristics &amp; Epidemiology  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Chronic immune‑mediated esophageal disease  </li>
<li style="margin-left: 0px;">Symptoms: dysphagia, food impaction, chest pain  </li>
<li style="margin-left: 0px;">Age range: infants → adults (all ages)  </li>
<li style="margin-left: 0px;">Atopic comorbidities in 60–80% (asthma, eczema, rhinitis)  </li>
</ul>
<details><summary><strong>2.1 Risk Factors  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Environmental triggers + genetic/epigenetic changes  </li>
<li style="margin-left: 0px;">Family history ↑ risk; “tip of iceberg” likely  </li>
</ul>
</div></details>
<details><summary><strong>2.2 Diagnostic Criteria (core triad)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Esophageal dysfunction symptoms  </li>
<li style="margin-left: 0px;">≥ 15 eos/hpf on biopsy  </li>
<li style="margin-left: 0px;">Exclude other eosinophilic disorders  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Interventions Overview  </strong></summary><div style="padding-left: 20px;">
<p><strong>All anti‑inflammatory and fibrostenotic therapies are addressed.</strong></p>
<details><summary><strong>3.1 Proton Pump Inhibitors (PPIs)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">“High‑dose” regimen (≈ 2× reflux dose)  </li>
<li style="margin-left: 0px;">Mechanisms: ↓ eotaxin‑3, barrier restoration, IL‑4/13 modulation  </li>
<li style="margin-left: 0px;">Conditional recommendation (low evidence)  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Swallowed Topical Steroids (STCs)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Budesonide oral suspension (BOS) or orodispersible tablet (BOT)  </li>
<li style="margin-left: 0px;">Fluticasone inhaler adapted for esophageal delivery  </li>
<li style="margin-left: 0px;">Strong recommendation (moderate evidence)  </li>
</ul>
<details><summary><strong>3.2.1 Dosing Highlights  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">BOS 2 mg BID; BOT 1 mg BID (adults)  </li>
<li style="margin-left: 0px;">Pediatric doses weight‑adjusted (0.5–2 mg/day)  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.3 Dietary Elimination Strategies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Empiric elimination diets (1‑FED, 2‑FED, 4‑FED, 6‑FED)  </li>
<li style="margin-left: 0px;">Elemental formula reserved for infants/severe refractory cases  </li>
<li style="margin-left: 0px;">Conditional recommendation (low evidence)  </li>
</ul>
<details><summary><strong>3.3.1 Efficacy Ranges  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">1‑FED ≈ 35–45% histologic remission  </li>
<li style="margin-left: 0px;">6‑FED ≈ 40–70% remission; most common triggers: milk, wheat  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.4 Biologics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Dupilumab</strong> (IL‑4Rα antagonist) – approved ≥12 yr, weight ≥ 40 kg  </li>
<li style="margin-left: 0px;">Conditional recommendation (moderate evidence)  </li>
<li style="margin-left: 0px;">Pediatric dupilumab (1–11 yr, ≥15 kg) – conditional (low evidence)  </li>
</ul>
<details><summary><strong>3.4.1 Trial Outcomes (Adults)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Histologic remission: 60% vs 5% placebo (p&lt;0.001)  </li>
<li style="margin-left: 0px;">Dysphagia score ↓ ≈ 22 points vs 10 points (p&lt;0.001)  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.5 Esophageal Dilation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Adjunct for fibrostenotic strictures causing dysphagia  </li>
<li style="margin-left: 0px;">Low‑quality evidence; conditional recommendation  </li>
</ul>
<details><summary><strong>3.5.1 Technique Principles  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">“Start low, go slow” incremental dilators  </li>
<li style="margin-left: 0px;">Target lumen ≈ 16 mm (adults) over ≤2 sessions  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3.6 Supportive Therapies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Feeding therapy for children with aversion/dysfunction  </li>
<li style="margin-left: 0px;">Nutritionist involvement for diet adherence &amp; growth monitoring  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Monitoring, Assessment &amp; Maintenance (first segment)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Evaluate <strong>symptoms</strong>, <strong>endoscopy</strong>, <strong>histology</strong> after 8–12 weeks of therapy  </li>
<li style="margin-left: 0px;">Use EREFS for endoscopic scoring (0‑9 scale)  </li>
<li style="margin-left: 0px;">Histologic target: &lt; 15 eos/hpf (&lt; 60 eos/mm²)  </li>
</ul>
<details><summary><strong>4.1 Response Metrics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Clinical improvement ↑ patient‑reported dysphagia scores  </li>
<li style="margin-left: 0px;">Endoscopic response: ΔEREFS ≤ 2 points  </li>
<li style="margin-left: 0px;">Histologic response: ↓ ≥ 85% eosinophils from baseline  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Maintenance Strategies (initial phase)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Continue effective therapy long‑term; disease recurs if stopped  </li>
<li style="margin-left: 0px;">Consider dose taper for STCs after remission (BOT 0.5 mg BID possible)  </li>
<li style="margin-left: 0px;">PPIs and diet can be maintained at effective doses  </li>
</ul>
<p><em>The above sections constitute the first portion of the guideline, covering study methodology, patient population, therapeutic options, and initial monitoring principles.</em></p>
</div></details>
</div></details>
<details><summary><strong>5. Safety &amp; Adverse Events  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Proton Pump Inhibitors  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Generally well tolerated → low serious AE rate  </li>
<li style="margin-left: 0px;">Possible ↑ risk: <em>C. difficile</em> infection (rare)  </li>
<li style="margin-left: 0px;">No confirmed CKD, dementia, bone fracture link  </li>
</ul>
</div></details>
<details><summary><strong>5.2 Swallowed Topical Steroids  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Most common AE: oral/esophageal candidiasis  </li>
<li style="margin-left: 20px;">BOS 3.8% → 23% across formulations  </li>
<li style="margin-left: 0px;">Adrenal insufficiency:</li>
<li style="margin-left: 20px;">Incidence ~0.5% in induction trials  </li>
<li style="margin-left: 20px;">Monitor cortisol if &gt;6 mo therapy  </li>
</ul>
<details><summary><strong>5.2.1 Management of Candidiasis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Topical clotrimazole or oral fluconazole course  </li>
<li style="margin-left: 0px;">Dose reduction or temporary cessation if severe  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5.3 Dietary Elimination  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Nutritional deficiencies possible → dietitian oversight required  </li>
<li style="margin-left: 0px;">Poor adherence ↑ risk of relapse (≈ 50% non‑adherent)  </li>
<li style="margin-left: 0px;">Elemental formula: high cost, may need gastrostomy  </li>
</ul>
</div></details>
<details><summary><strong>5.4 Biologics (Dupilumab)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Injection site erythema → most frequent AE  </li>
<li style="margin-left: 0px;">Rare arthralgia; no increased infection risk reported  </li>
<li style="margin-left: 0px;">No routine laboratory monitoring needed  </li>
</ul>
</div></details>
<details><summary><strong>5.5 Esophageal Dilation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perforation rate ≈ 0.05% → rare but serious  </li>
<li style="margin-left: 0px;">Post‑procedure hospitalization &lt; 1%  </li>
<li style="margin-left: 0px;">“Start low, go slow” reduces complication risk  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Subgroup &amp; Sensitivity Analyses  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Age‑Based Subgroups  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Adults ≥12 yr: dupilumab approved; higher response rates  </li>
<li style="margin-left: 0px;">Children 1–11 yr: lower histologic remission (68% high dose)  </li>
</ul>
<details><summary><strong>6.1.1 Pediatric Growth Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Monitor height, weight, BMI z‑scores every 3 mo  </li>
<li style="margin-left: 0px;">STC‑related adrenal suppression rare but assess if &gt;12 mo  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6.2 Atopic Burden Subgroups  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">≥3 concurrent atopic diseases → ↑ EoE suspicion  </li>
<li style="margin-left: 0px;">May predict better response to dupilumab (shared pathway)  </li>
</ul>
</div></details>
<details><summary><strong>6.3 Fibrostenotic Phenotype  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Strictures present → combine anti‑inflammatory + dilation  </li>
<li style="margin-left: 0px;">Higher relapse risk if inflammation untreated alone  </li>
</ul>
<details><summary><strong>6.3.1 Endoscopic Findings Correlating with Fibrosis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Rings, strictures, reduced distensibility index (&lt; 4.5 mm²)  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6.4 Treatment‑Naïve vs. Refractory Subgroups  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior STC failure → consider dupilumab or step‑up diet  </li>
<li style="margin-left: 0px;">PPI non‑responders: proceed to STC or biologic  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Interpretation &amp; Clinical Implications  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>7.1 Therapeutic Algorithm Summary  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Initial choice: medication vs diet (shared decision)  </li>
<li style="margin-left: 0px;">PPIs or STC first‑line; assess response at 8–12 wk  </li>
<li style="margin-left: 0px;">Non‑responders → dupilumab or intensified diet (4‑FED/6‑FED)  </li>
</ul>
<details><summary><strong>7.1.1 Dose Optimization Pathway  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Successful remission → consider dose taper (STC)  </li>
<li style="margin-left: 0px;">Maintain lowest effective dose for maintenance  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7.2 Long‑Term Disease Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Chronic condition → indefinite therapy recommended  </li>
<li style="margin-left: 0px;">Regular endoscopic surveillance every 12–24 mo if stable  </li>
<li style="margin-left: 0px;">Escalate to combination therapy only if persistent fibrostenosis  </li>
</ul>
</div></details>
<details><summary><strong>7.3 Cost &amp; Access Considerations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Biologics high cost → insurance prior authorization often needed  </li>
<li style="margin-left: 0px;">Generic PPIs inexpensive; preferred for initial trial  </li>
<li style="margin-left: 0px;">Dietitian services may be reimbursed under nutrition counseling codes  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Emerging Research &amp; Future Directions  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>8.1 Biomarker Development  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Non‑invasive: Cytosponge, Esophageal String Test (eotaxin‑3)  </li>
<li style="margin-left: 0px;">Aim: replace routine biopsies for monitoring  </li>
</ul>
</div></details>
<details><summary><strong>8.2 Novel Therapeutics Pipeline  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Anti‑TSLP (tezepelumab), anti‑IL‑15, JAK inhibitors in phase II trials  </li>
<li style="margin-left: 0px;">New topical steroid delivery systems (nanoparticle gels) under investigation  </li>
</ul>
</div></details>
<details><summary><strong>8.3 Phenotype &amp; Endotype Stratification  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">I‑SEE scoring integration with treatment selection pending validation  </li>
<li style="margin-left: 0px;">Genetic/epigenetic markers (e.g., TGF‑β SNPs) explored for response prediction  </li>
</ul>
</div></details>
<details><summary><strong>8.4 Comparative Effectiveness Studies Needed  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Head‑to‑head RCTs: PPIs vs STC vs diet vs biologic  </li>
<li style="margin-left: 0px;">Longitudinal studies on fibrosis progression despite histologic remission  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Maintenance Therapy  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>9.1 Rationale for Continuation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Disease chronic → relapse if stopped  </li>
<li style="margin-left: 0px;">Fibrostenosis progression without ongoing control  </li>
</ul>
</div></details>
<details><summary><strong>9.2 Pharmacologic Maintenance Options  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Continue effective STC at lowest dose maintaining remission  </li>
<li style="margin-left: 0px;">High‑dose PPI maintenance acceptable if responsive  </li>
</ul>
<details><summary><strong>9.2.1 Dose Reduction Strategies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">BOS 0.5 mg BID after ≥6 mo remission  </li>
<li style="margin-left: 0px;">Fluticasone 110 µg BID minimum effective dose  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9.3 Dietary Maintenance Options  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Continue empiric elimination diet long‑term if tolerated  </li>
<li style="margin-left: 0px;">Periodic re‑evaluation for trigger identification every 12–24 mo  </li>
</ul>
<details><summary><strong>9.3.1 “Diet Holiday” Concept  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Temporary relaxation during vacations or special events  </li>
<li style="margin-left: 0px;">Bridge with medical therapy to maintain remission  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9.4 Biologic Maintenance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Dupilumab continued indefinitely; assess response annually  </li>
<li style="margin-left: 0px;">Monitor injection site reactions, eosinophil counts periodically  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Monitoring &amp; Evaluation of Response  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>10.1 Timing of Assessments  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Endoscopy + biopsies at 8–12 wk after therapy initiation  </li>
<li style="margin-left: 0px;">Repeat monitoring every 12 mo if stable; sooner if symptoms recur  </li>
</ul>
</div></details>
<details><summary><strong>10.2 Clinical Symptom Assessment  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Dysphagia score (0‑10) → aim ↓≥ 3 points  </li>
<li style="margin-left: 0px;">Record IMPACT behaviors (IMBIBE, MODIFY, PROLONG, AVOID, CHEW, TURN)  </li>
</ul>
<details><summary><strong>10.2.1 Symptom Tools  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Dysphagia Symptom Questionnaire (DSQ) validated in adults  </li>
<li style="margin-left: 0px;">Pediatric symptom diaries for feeding dysfunction  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10.3 Endoscopic Scoring (EREFS)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Edema, Rings, Exudates, Furrows, Strictures → total 0‑9  </li>
<li style="margin-left: 0px;">Treatment response threshold: ΔEREFS ≤ 2 points  </li>
</ul>
<details><summary><strong>10.3.1 Fibrostenotic Indicators  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Persistent rings or strictures → consider dilation adjunct  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10.4 Histologic Evaluation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Peak eos/hpf &lt; 15 (or &lt; 60 eos/mm²) target  </li>
<li style="margin-left: 0px;">Report additional features: basal zone hyperplasia, lamina propria fibrosis (EoEHSS)  </li>
</ul>
<details><summary><strong>10.4.1 Deep Remission Definition  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Symptom resolution + EREFS 0 + eos/hpf &lt; 5  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10.5 Non‑Invasive Monitoring Options  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Cytosponge sensitivity 75%, specificity 86% vs biopsy  </li>
<li style="margin-left: 0px;">Esophageal String Test eotaxin‑3 AUC 0.83 for activity  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11. Pediatric‑Specific Considerations  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>11.1 Growth &amp; Development Goals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Maintain height, weight, BMI z‑scores within normal range  </li>
<li style="margin-left: 0px;">Monitor every 3 mo; involve pediatric endocrinology if faltering  </li>
</ul>
</div></details>
<details><summary><strong>11.2 Feeding Therapy Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Evaluate for avoidant/restrictive food intake disorder (ARFID)  </li>
<li style="margin-left: 0px;">Refer to feeding therapist when dysphagia or aversion present  </li>
</ul>
<details><summary><strong>11.2.1 Multidisciplinary Approach  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Gastroenterologist ↔ dietitian ↔ feeding therapist ↔ allergist  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11.3 Diagnostic Imaging in Children  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Esophagram recommended for suspected fibrostenosis (very low evidence)  </li>
<li style="margin-left: 0px;">EndoFLIP optional where available for distensibility assessment  </li>
</ul>
</div></details>
<details><summary><strong>11.4 Dietary Management in Pediatrics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Start with less‑restrictive diet (1‑FED or 2‑FED) preferred  </li>
<li style="margin-left: 0px;">Elemental formula reserved for infants or severe refractory cases  </li>
</ul>
<details><summary><strong>11.4.1 Nutritional Support  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Registered dietitian ensures adequate calories, micronutrients  </li>
<li style="margin-left: 0px;">Monitor for vitamin D, iron, zinc deficiencies quarterly  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>11.5 Medication Dosing in Children  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">PPI: 2 mg/kg/day (max 40 mg BID)  </li>
<li style="margin-left: 0px;">BOS: 0.5–1 mg BID based on weight tier  </li>
<li style="margin-left: 0px;">Dupilumab: 200 mg q2w for 15‑30 kg; 300 mg weekly ≥ 40 kg  </li>
</ul>
</div></details>
<details><summary><strong>11.6 Adverse Event Monitoring in Children  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Screen for adrenal insufficiency if STC &gt; 12 mo  </li>
<li style="margin-left: 0px;">Watch for growth deceleration with chronic steroid use  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>12. Key Concepts &amp; Expert Advice  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>12.1 Diagnostic Nuances  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform endoscopy off any diet/PPI to maximize sensitivity  </li>
<li style="margin-left: 0px;">Assess for non‑EoE eosinophilic disorders (GERD, infections)  </li>
</ul>
</div></details>
<details><summary><strong>12.2 Treatment Selection Principles  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Shared decision‑making essential; consider patient preference, cost, lifestyle  </li>
<li style="margin-left: 0px;">No superiority data → choose medication vs diet based on individual factors  </li>
</ul>
</div></details>
<details><summary><strong>12.3 Monitoring Philosophy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Do not rely solely on symptoms; combine clinical, endoscopic, histologic data  </li>
<li style="margin-left: 0px;">“Deep remission” ideal but achievable in minority of patients  </li>
</ul>
</div></details>
<details><summary><strong>12.4 Long‑Term Disease Outlook  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">EoE does not resolve spontaneously; maintenance required indefinitely  </li>
<li style="margin-left: 0px;">Early treatment may limit fibrostenotic progression  </li>
</ul>
</div></details>
<details><summary><strong>12.5 Research Gaps Highlighted  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Need head‑to‑head RCTs comparing PPIs, STCs, diets, biologics  </li>
<li style="margin-left: 0px;">Development of validated non‑invasive biomarkers critical  </li>
<li style="margin-left: 0px;">Phenotype/endotype classification to personalize therapy pending validation  </li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
